Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Mini Review - Journal of Medical Oncology and Therapeutics (2023) Volume 8, Issue 3

Immunotherapy and Its Applications in Oncology

Andishe Gentry *

Department of Paediatric Haematology and Oncology, Medical University of Vienna, Austria

*Corresponding Author:
Andishe Gentry
Department of Paediatric Haematology and Oncology, Medical University of Vienna, Austria
E-mail: E-mail:

Received: 03-April-2023, Manuscript No. JMOT-23-100255; Editor assigned: 12-Apr-2023, PreQC No. JMOT-23-100255 (PQ); Reviewed:29-Apr-2023, QC No. JMOT-23-100255; Revised:04-May-2023, Manuscript No. JMOT-23-100255 (R); Published:12-May-2023, DOI:10.35841/ jmot-8.3.142

Citation: Gentry A. Immunotherapy and Its Applications in Oncology. J Med Oncl Ther. 2023;8(3):142

Visit for more related articles at Journal of Medical Oncology and Therapeutics


Immunotherapy has emerged as a groundbreaking approach in the field of oncology, harnessing the power of the immune system to combat cancer. This article explores the latest advancements in immunotherapy and its applications in the treatment of various types of cancer. It discusses key immunotherapeutic strategies, including immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines, highlighting their mechanisms of action, clinical efficacy, and ongoing research efforts


Immunotherapy, Cancer immunotherapy, Immune response.


Traditional cancer treatments often focus on directly targeting cancer cells. However, the immune system plays a crucial role in recognizing and eliminating cancer cells, making immunotherapy an attractive therapeutic avenue. This article provides an overview of recent breakthroughs in immunotherapy and its transformative impact on cancer treatment. Programmed Cell Death Protein 1 (PD-1) Inhibitors: Antibodies targeting the PD-1 receptor, such as pembrolizumab and nivolumab, have demonstrated remarkable success in multiple cancer types, including melanoma, non-small cell lung cancer, and renal cell carcinoma.These inhibitors restore T-cellactivity by blocking the PD-1 pathway, thereby unleashing the immune response against cancer cells.Drugs like ipilimumab target CTLA-4, enhancing T-cell activation and promoting anti-tumor immune responses. CTLA-4 inhibitors have shown efficacy in melanoma and are being investigated in other malignancies.

Chimeric Antigen Receptor (CAR) T-cell Therapy: CAR T-cell therapy involves modifying a patient's T cells to express a synthetic receptor that recognizes cancer-specific antigens. Approved CAR T-cell therapies, such as axicabtagene ciloleucel and tisagenlecleucel, have shown impressive results in hematologic malignancies, including certain types of leukemia and lymphoma [1].

Tumor-Infiltrating Lymphocyte (TIL) Therapy: TIL therapy involves extracting immune cells from a patient's tumor, expanding them in the laboratory, and reinfusing them back into the patient. Promising results have been observed in melanoma and other solid tumors, although further research is needed to optimize its efficacy and applicability

 Therapeutic cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells. Sipuleucel-T, an autologous cellular immunotherapy, has been approved for metastatic castration-resistant prostate cancer, demonstrating improved overall survival.vaccines targeting cancer-causing viruses, such as human papillomavirus (HPV) and hepatitis B virus (HBV), have been successful in preventing related malignancies, including cervical and liver cancers [2].

While immunotherapy has shown remarkable efficacy, challenges remain. Some patients do not respond to treatment, and others experience immune-related adverse events. Ongoing research focuses on biomarker identification, combination therapies, and optimizing treatment protocols to improve patient selection and outcomes. Additionally, efforts are underway to expand immunotherapy to additional cancer types and develop novel immunotherapeutic agents. Combination Immunotherapies: The field of immunotherapy is rapidly evolving with the exploration of combination approaches. Combining different immunotherapeutic agents, such as immune checkpoint inhibitors, or combining immunotherapy with other treatment modalities like chemotherapy or radiation therapy, has shown potential in enhancing treatment responses and overcoming resistance mechanisms. These synergistic combinations are being investigated in clinical trials across various cancer types. dentifying reliable predictive biomarkers is crucial to optimize patient selection for immunotherapy. Biomarkers such as programmed death ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and microsatellite instability (MSI) have been associated with response to certain immunotherapies. Ongoing research aims to refine and validate these biomarkers, as well as explore novel predictive markers, to guide treatment decisions and improve patient outcomes [3].

 While immunotherapy has demonstrated significant clinical benefits, not all patients respond or develop resistance over time. Mechanisms of resistance include loss of antigen expression, activation of alternative immune checkpoints, and immunosuppressive tumor microenvironment. Investigating these resistance mechanisms and developing strategies to overcome them are active areas of research to enhance the effectiveness of immunotherapy. Initially, immunotherapy showed remarkable success in hematologic malignancies, particularly in certain types of leukemia and lymphoma. However, efforts are now focused on expanding the application of immunotherapy to solid tumors, including lung, breast, colorectal, and pancreatic cancers. Overcoming the unique challenges posed by solid tumors, such as tumor heterogeneity and immune evasion mechanisms, remains a priority in this area of research [4,].

One of the remarkable aspects of immunotherapy is the potential for durable responses and long-term benefits. Some patients experience prolonged periods of disease control or even complete remission, offering the possibility of long term survival. Understanding the factors contributing to sustained responses and identifying strategies to enhance durability are important for maximizing the clinical impact of immunotherapy. While immunotherapy generally has a favorable safety profile compared to traditional treatments, immune-related adverse events (irAEs) can occur. These irAEs, affecting various organs, are a result of immune system activation. Prompt recognition and management of these toxicities are essential to minimize their impact and ensure the safety and well-being of patients receiving immunotherapy [5].


Immunotherapy has revolutionized cancer treatment by harnessing the immune system's capabilities to fight cancer. The advances discussed in this article underscore the growing importance of immunotherapy in various malignancies. Continued research, clinical trials, and collaborations are essential to refine existing immunotherapies, discover new targets, and expand the reach of immunotherapy, ultimately leading to improved outcomes and a brighter future for cancer patients.


  1. Stylianopoulos T, Jain RK. Design considerations for nanotherapeutics in oncology. Nanomed Nanotechnol Biol Med. 2015;11(8):1893-907.
  2. Indexed at, Google Scholar, Cross Ref

  3. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Clin Oncol. 2006;24(18):2932-47.
  4. Indexed at, Google Scholar, Cross Ref

  5. Saylors III RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19(15):3463-9.
  6. Indexed at, Google Scholar, Cross Ref

  7. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31(15):1803-5.
  8. Indexed at, Google Scholar, Cross Ref

  9. Anderson AR, Quaranta V. Integrative mathematical oncology. Nat Rev Cancer. 2008;8 (3):227-34.
  10. Indexed at, Google Scholar, Cross Ref


Get the App